Biotechnology Company Forms Exclusive Arrangement With Vaccine Institute For NMIBC Treatment Supply

Poised to transform the landscape of cancer treatment, ImmunityBio, Inc. and the Serum Institute of India (SII) have entered into an exclusive arrangement to tackle one of the most pressing challenges in oncology care: the global shortage of Bacillus Calmette-Guerin (BCG). This collaboration aims to secure a steady supply of both standard BCG (sBCG) and a pioneering next-generation recombinant BCG (iBCG), offering a ray of hope for patients battling various cancer types, particularly non-muscle invasive bladder cancer (NMIBC). $ImmunityBio(IBRX.US)$